IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Steven M. Bessette et al.

Atty. Ref.:

4380-151

Serial No.: 10/759,177

Group:

1651

Filed: January 20, 2004

Examiner:

LILLING, Herbert

For: CANCER TREATMENT COMPOSITIONS AND METHOD USING

NATURAL PLANT ESSENTIAL OILS

* * * * * * * * * *


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450


Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In compliance with the duty of disclosure requirements under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant(s) concurrently submit herewith a Form PTO-1449 that lists documents containing information that may be considered material to the examination of the above-captioned patent application. A copy of each cited document is also being submitted herewith, if required. No representation is made or intended that (1) more relevant information does not exist, (2) the order of presentation of the information in any way reflects their relative pertinence to the above-captioned patent application, or (3) a search has been made. The Examiner is specifically requested not to rely solely on the information submitted herewith. Applicant(s) respectfully request(s) that the submitted information be expressly considered during the prosecution of this application and that all cited document(s) be made of record therein and appear among the "References Cited" section of any patent to issue therefrom. At least one of the boxes below applies to the present application.

- 1. A This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
 - a. Contingent Request to Treat Under 37 C.F.R. § 1.97(c). In the event a first Office Action has been mailed prior to filing of the present Information Disclosure Statement and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(c) and charge the undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p).





publication date should not be construed as an admission that the information contained in the document was actually published on such listed publication date.

Please grant any extension(s) of time deemed necessary for entry of this communication. The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper filed hereafter) to Deposit Account No. 14-1140.

Respectfully submitted,

NIXON & VANDERHYE P.C.

Date: April 1,2005

By:

Villem F. Gadiano

Reg. No. 37,136

WFG:ewm

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

	7			
Sh	eet	1	Ωf	1

INFORMATION DISCLOSURE CITATION

(Use several sheety in ecessary)

Atty. Docket No.	Serial No.
4380-151	10/759,177
Applicant	

Steven M. Bessette et al.

Filing Date Group

January 20, 2004 1651

*EXAMINER DOCUMENTS OLASS CURSUASS FILING DATE						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,261,989	04/1981	Sasaki et al.			
	5,322,844	06/1994	Aranda et al.			
	5,387,584	02/1995	Schnur			
	5,795,910	08/1998	Giese et al.			
	5,830,887	11/1998	Kelly			
	5,911,995	06/1999	Uckun			
	6,147,107	11/2000	Dent et al.			
	6,268,163	07/2001	Kongsbak et al.			

FOREIGN PATENT DOCUMENTS

						TRANS	LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	EP 0 448 029 A2	03/1991	EUROPE				
	WO 98/48790	11/1998	PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

 	OTTEN BOOOMENTO (moldaning Admon, Title, Bate, Tertificity pages, etc.)				
	Azuine, M.A. et al., "Chemopreventive efficacy of betal leaf extract and its constituents on 7,12-				
dimethylbenz(a)anthracene induced carcinogenesis and their effect on drug detoxification sustem in mouse skin", Inc					
	Journal of Experimental Biology, 29(4):346-351 (1991)				
	Baker, P.R. et al., "Cell signaling and basement membrane degradation by breast cancer cells", British Journal of Cancer,				
	69(Suppl. 21): 18 (1994)				
	Kinoshita, E. et al., "Activation of MAP kinase cascade induced by human pancreatic phospholipase A ₂ in a human				
	pancreatic cancer cell line", FEBS Letters, 407(3):343-346 (1997)				
	Nayfield, S.G., "Tamoxifen's role in chemoprevention of breast cancer: an update", Journal of Cellular Biochemistry,				
	Suppl. 22:42-50 (1995)				
	Strobl, J.S. et al., "Mitogenic signal transduction in human breast cancer cells", General Pharmacology, 26(8):1643-1649				
	(1995)				
	Tzanakakis, G.N. et al., "Inhibition of hepatic metastasis from a human pancreatic adenocarcinoma (RWP-2) in the nude				
	mouse by prostacyclin, forskolin, and ketoconazole", Cancer, 65(3):446-451 (1990)				
	Yokota, H. et al., "Enhancement of UDP-glucuronyltransferase, UDP-glucose dehydrogenase, and glutathione S-				
	transferase activities in rat liver by dietary administration of eugenol", Biochemical Pharmacology, 37(5):799-802 (1988)				
	·				
 -					

*Examiner		Date Considered				
Francisco Initial if reference apprilated whether as not disting in its conference with MDED 600 D						

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.